IPP Bureau
Kaiser Permanente’s study highlights power of genetics in preventing heart disease
By IPP Bureau - November 14, 2025
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
By IPP Bureau - November 14, 2025
Fenebrutinib targets cells in the immune system known as B cells and microglia
LANXESS set to showcase cutting-edge infection control solutions
By IPP Bureau - November 14, 2025
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report
By IPP Bureau - November 14, 2025
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Enzymit and Cosun chart breakthrough in cell-free hyaluronic acid production
By IPP Bureau - November 14, 2025
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
By IPP Bureau - November 14, 2025
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
By IPP Bureau - November 14, 2025
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer
By IPP Bureau - November 14, 2025
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Lupin receives EIR from FDA for its Aurangabad facility
By IPP Bureau - November 13, 2025
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million
By IPP Bureau - November 13, 2025
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg
By IPP Bureau - November 13, 2025
Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag
By IPP Bureau - November 13, 2025
Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities
By IPP Bureau - November 13, 2025
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Philogen updates on Fibromun clinical study developments
By IPP Bureau - November 13, 2025
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components
By IPP Bureau - November 13, 2025
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
